Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to $35.9 million.

  • Lineage Cell Therapeutics' Cash from Financing Activities rose 61233.33% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.3 million, marking a year-over-year increase of 100.60%. This contributed to the annual value of $35.9 million for FY2024, which is 458.26% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Cash from Financing Activities of $35.9 million as of FY2024, which was up 458.26% from $6.4 million recorded in FY2023.
  • Lineage Cell Therapeutics' 5-year Cash from Financing Activities high stood at $36.9 million for FY2021, and its period low was $1.6 million during FY2022.
  • Moreover, its 3-year median value for Cash from Financing Activities was $6.4 million (2023), whereas its average is $14.6 million.
  • In the last 5 years, Lineage Cell Therapeutics' Cash from Financing Activities skyrocketed by 4,740.36% in 2020 and then tumbled by 95.58% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Cash from Financing Activities (Yearly) stood at $29.9 million in 2020, then grew by 23.66% to $36.9 million in 2021, then crashed by 95.58% to $1.6 million in 2022, then spiked by 293.57% to $6.4 million in 2023, then spiked by 458.26% to $35.9 million in 2024.